PCM
VIRX

Palisade Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Palisade Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,384
Closed -$8.07M – 505
2014
Q3 		$8.07M Sell
5,384
-2,272
-30% -$3.29M 0.2% 199
2014
Q2 		$10.5M Buy
7,656
+1,088
+17% +$1.26M 0.25% 164
2014
Q1 		$9.12M Buy
+6,568
New +$7.64M 0.22% 180

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Palisade Capital Management's VIRX Position: Q4 2014 in Review

Palisade Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 5,384 shares — an estimated $8.07M sold.

Palisade Capital Management first reported a position in VIRX in Q1 2014 and held it in 3 quarters. The position peaked at $10.5M in Q2 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

  • Palisade Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Palisade Capital Management sold 5,384 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $8.07M.
  • Palisade Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 3 quarters.
  • Palisade Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $10.5M in Q2 2014.
  • 78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Palisade Capital Management's 13F filing for Q4 2014, filed 11 Feb 2015.